Effect of dystonia and botulinum toxin treatment on health‐related quality of life
Identifieur interne : 007F31 ( Main/Merge ); précédent : 007F30; suivant : 007F32Effect of dystonia and botulinum toxin treatment on health‐related quality of life
Auteurs : Gudex [Danemark] ; Maurice R. Hawthorne [Royaume-Uni] ; Anthony G. Butler [Royaume-Uni] ; Philip Duffey [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-11.
English descriptors
- KwdEn :
- Adult, Anti-Dyskinesia Agents (therapeutic use), Botulinum Toxins (therapeutic use), Botulinum toxin, Chi-Square Distribution, Cohort Studies, Dystonia, Dystonia (drug therapy), Dystonia (psychology), EuroQol, Female, Health‐related quality of life, Humans, Male, Middle Aged, Prospective Studies, Quality of Life, Questionnaires, SF‐36.
- MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug therapy : Dystonia.
- psychology : Dystonia.
- Adult, Chi-Square Distribution, Cohort Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Quality of Life, Questionnaires.
Abstract
In view of the steadily rising demand for treatment of dystonia with botulinum toxin (BT), a relatively expensive neurologic paralytic agent, an exploratory study was undertaken to assess the extent to which dystonia and BT treatment affect the quality of people's lives. One hundred thirty adults with a current diagnosis of dystonia completed two generic measures of health‐related quality of life (HRQoL) at regular intervals over a minimum of 6 months. One hundred two participants were receiving regular injections of BT; 28 were not taking BT. The HRQoL instruments used were the EuroQol and the Short Form 36 health survey questionnaire (SF‐36). Compared with general population samples, study participants reported greater impairment on all EuroQol and SF‐36 dimensions and gave a lower rating to their own health status. Participants with nonfocal dystonia had significantly more problems with usual activities than participants with focal dystonia, and a higher number had problems with mobility and self‐care. The groups reported similar levels of pain and emotional well‐being. Small improvements in HRQoL were seen after the administration of BT, although few of these were statistically significant. The study results offer further psychometric evidence for the discriminant and construct validity of both the EuroQol and the SF‐36.
Url:
DOI: 10.1002/mds.870130613
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001755
- to stream Istex, to step Curation: 001755
- to stream Istex, to step Checkpoint: 003754
- to stream PubMed, to step Corpus: 004307
- to stream PubMed, to step Curation: 004307
- to stream PubMed, to step Checkpoint: 004448
- to stream Ncbi, to step Merge: 005076
- to stream Ncbi, to step Curation: 005076
- to stream Ncbi, to step Checkpoint: 005076
Links to Exploration step
ISTEX:A427930BFE364F3FACBEA4C18503E88BE303E701Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of dystonia and botulinum toxin treatment on health‐related quality of life</title><author><name sortKey="Gudex" sort="Gudex" uniqKey="Gudex" last="Gudex">Gudex</name></author><author><name sortKey="Hawthorne, Maurice R" sort="Hawthorne, Maurice R" uniqKey="Hawthorne M" first="Maurice R." last="Hawthorne">Maurice R. Hawthorne</name></author><author><name sortKey="Butler, Anthony G" sort="Butler, Anthony G" uniqKey="Butler A" first="Anthony G." last="Butler">Anthony G. Butler</name></author><author><name sortKey="Duffey, Philip" sort="Duffey, Philip" uniqKey="Duffey P" first="Philip" last="Duffey">Philip Duffey</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A427930BFE364F3FACBEA4C18503E88BE303E701</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130613</idno><idno type="url">https://api.istex.fr/document/A427930BFE364F3FACBEA4C18503E88BE303E701/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001755</idno><idno type="wicri:Area/Istex/Curation">001755</idno><idno type="wicri:Area/Istex/Checkpoint">003754</idno><idno type="wicri:doubleKey">0885-3185:1998:Gudex:effect:of:dystonia</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9827619</idno><idno type="wicri:Area/PubMed/Corpus">004307</idno><idno type="wicri:Area/PubMed/Curation">004307</idno><idno type="wicri:Area/PubMed/Checkpoint">004448</idno><idno type="wicri:Area/Ncbi/Merge">005076</idno><idno type="wicri:Area/Ncbi/Curation">005076</idno><idno type="wicri:Area/Ncbi/Checkpoint">005076</idno><idno type="wicri:doubleKey">0885-3185:1998:Gudex C:effect:of:dystonia</idno><idno type="wicri:Area/Main/Merge">007F31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of dystonia and botulinum toxin treatment on health‐related quality of life</title><author><name sortKey="Gudex" sort="Gudex" uniqKey="Gudex" last="Gudex">Gudex</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Psychiatric Research Unit, Frederiksborg General Hospital</wicri:regionArea><wicri:noRegion>Frederiksborg General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hawthorne, Maurice R" sort="Hawthorne, Maurice R" uniqKey="Hawthorne M" first="Maurice R." last="Hawthorne">Maurice R. Hawthorne</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Botulinum Toxin Clinic, North Riding Infirmary, Middlesborough</wicri:regionArea><wicri:noRegion>Middlesborough</wicri:noRegion></affiliation></author><author><name sortKey="Butler, Anthony G" sort="Butler, Anthony G" uniqKey="Butler A" first="Anthony G." last="Butler">Anthony G. Butler</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hunters Moor Regional Rehabilitation Centre, University of Newcastle‐upon‐Tyne</wicri:regionArea><wicri:noRegion>University of Newcastle‐upon‐Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Duffey, Philip" sort="Duffey, Philip" uniqKey="Duffey P" first="Philip" last="Duffey">Philip Duffey</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, University of Newcastle‐upon‐Tyne</wicri:regionArea><wicri:noRegion>University of Newcastle‐upon‐Tyne</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-11">1998-11</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="941">941</biblScope><biblScope unit="page" to="946">946</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A427930BFE364F3FACBEA4C18503E88BE303E701</idno><idno type="DOI">10.1002/mds.870130613</idno><idno type="ArticleID">MDS870130613</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Botulinum Toxins (therapeutic use)</term><term>Botulinum toxin</term><term>Chi-Square Distribution</term><term>Cohort Studies</term><term>Dystonia</term><term>Dystonia (drug therapy)</term><term>Dystonia (psychology)</term><term>EuroQol</term><term>Female</term><term>Health‐related quality of life</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Quality of Life</term><term>Questionnaires</term><term>SF‐36</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Chi-Square Distribution</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Quality of Life</term><term>Questionnaires</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In view of the steadily rising demand for treatment of dystonia with botulinum toxin (BT), a relatively expensive neurologic paralytic agent, an exploratory study was undertaken to assess the extent to which dystonia and BT treatment affect the quality of people's lives. One hundred thirty adults with a current diagnosis of dystonia completed two generic measures of health‐related quality of life (HRQoL) at regular intervals over a minimum of 6 months. One hundred two participants were receiving regular injections of BT; 28 were not taking BT. The HRQoL instruments used were the EuroQol and the Short Form 36 health survey questionnaire (SF‐36). Compared with general population samples, study participants reported greater impairment on all EuroQol and SF‐36 dimensions and gave a lower rating to their own health status. Participants with nonfocal dystonia had significantly more problems with usual activities than participants with focal dystonia, and a higher number had problems with mobility and self‐care. The groups reported similar levels of pain and emotional well‐being. Small improvements in HRQoL were seen after the administration of BT, although few of these were statistically significant. The study results offer further psychometric evidence for the discriminant and construct validity of both the EuroQol and the SF‐36.</div></front></TEI><double doi="10.1002/mds.870130613"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of dystonia and botulinum toxin treatment on health‐related quality of life</title><author><name sortKey="Gudex" sort="Gudex" uniqKey="Gudex" last="Gudex">Gudex</name></author><author><name sortKey="Hawthorne, Maurice R" sort="Hawthorne, Maurice R" uniqKey="Hawthorne M" first="Maurice R." last="Hawthorne">Maurice R. Hawthorne</name></author><author><name sortKey="Butler, Anthony G" sort="Butler, Anthony G" uniqKey="Butler A" first="Anthony G." last="Butler">Anthony G. Butler</name></author><author><name sortKey="Duffey, Philip" sort="Duffey, Philip" uniqKey="Duffey P" first="Philip" last="Duffey">Philip Duffey</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A427930BFE364F3FACBEA4C18503E88BE303E701</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130613</idno><idno type="url">https://api.istex.fr/document/A427930BFE364F3FACBEA4C18503E88BE303E701/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001755</idno><idno type="wicri:Area/Istex/Curation">001755</idno><idno type="wicri:Area/Istex/Checkpoint">003754</idno><idno type="wicri:doubleKey">0885-3185:1998:Gudex:effect:of:dystonia</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of dystonia and botulinum toxin treatment on health‐related quality of life</title><author><name sortKey="Gudex" sort="Gudex" uniqKey="Gudex" last="Gudex">Gudex</name><affiliation wicri:level="1"><country xml:lang="fr">Danemark</country><wicri:regionArea>Psychiatric Research Unit, Frederiksborg General Hospital</wicri:regionArea><wicri:noRegion>Frederiksborg General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hawthorne, Maurice R" sort="Hawthorne, Maurice R" uniqKey="Hawthorne M" first="Maurice R." last="Hawthorne">Maurice R. Hawthorne</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Botulinum Toxin Clinic, North Riding Infirmary, Middlesborough</wicri:regionArea><wicri:noRegion>Middlesborough</wicri:noRegion></affiliation></author><author><name sortKey="Butler, Anthony G" sort="Butler, Anthony G" uniqKey="Butler A" first="Anthony G." last="Butler">Anthony G. Butler</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hunters Moor Regional Rehabilitation Centre, University of Newcastle‐upon‐Tyne</wicri:regionArea><wicri:noRegion>University of Newcastle‐upon‐Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Duffey, Philip" sort="Duffey, Philip" uniqKey="Duffey P" first="Philip" last="Duffey">Philip Duffey</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Clinical Neurosciences, University of Newcastle‐upon‐Tyne</wicri:regionArea><wicri:noRegion>University of Newcastle‐upon‐Tyne</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-11">1998-11</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="941">941</biblScope><biblScope unit="page" to="946">946</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A427930BFE364F3FACBEA4C18503E88BE303E701</idno><idno type="DOI">10.1002/mds.870130613</idno><idno type="ArticleID">MDS870130613</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Botulinum toxin</term><term>Dystonia</term><term>EuroQol</term><term>Health‐related quality of life</term><term>SF‐36</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In view of the steadily rising demand for treatment of dystonia with botulinum toxin (BT), a relatively expensive neurologic paralytic agent, an exploratory study was undertaken to assess the extent to which dystonia and BT treatment affect the quality of people's lives. One hundred thirty adults with a current diagnosis of dystonia completed two generic measures of health‐related quality of life (HRQoL) at regular intervals over a minimum of 6 months. One hundred two participants were receiving regular injections of BT; 28 were not taking BT. The HRQoL instruments used were the EuroQol and the Short Form 36 health survey questionnaire (SF‐36). Compared with general population samples, study participants reported greater impairment on all EuroQol and SF‐36 dimensions and gave a lower rating to their own health status. Participants with nonfocal dystonia had significantly more problems with usual activities than participants with focal dystonia, and a higher number had problems with mobility and self‐care. The groups reported similar levels of pain and emotional well‐being. Small improvements in HRQoL were seen after the administration of BT, although few of these were statistically significant. The study results offer further psychometric evidence for the discriminant and construct validity of both the EuroQol and the SF‐36.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of dystonia and botulinum toxin treatment on health-related quality of life.</title><author><name sortKey="Gudex, C M" sort="Gudex, C M" uniqKey="Gudex C" first="C M" last="Gudex">C M Gudex</name><affiliation wicri:level="1"><nlm:affiliation>Psychiatric Research Unit, Frederiksborg General Hospital, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Psychiatric Research Unit, Frederiksborg General Hospital</wicri:regionArea><wicri:noRegion>Frederiksborg General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hawthorne, M R" sort="Hawthorne, M R" uniqKey="Hawthorne M" first="M R" last="Hawthorne">M R Hawthorne</name></author><author><name sortKey="Butler, A G" sort="Butler, A G" uniqKey="Butler A" first="A G" last="Butler">A G Butler</name></author><author><name sortKey="Duffey, P" sort="Duffey, P" uniqKey="Duffey P" first="P" last="Duffey">P. Duffey</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9827619</idno><idno type="pmid">9827619</idno><idno type="doi">10.1002/mds.870130613</idno><idno type="wicri:Area/PubMed/Corpus">004307</idno><idno type="wicri:Area/PubMed/Curation">004307</idno><idno type="wicri:Area/PubMed/Checkpoint">004448</idno><idno type="wicri:Area/Ncbi/Merge">005076</idno><idno type="wicri:Area/Ncbi/Curation">005076</idno><idno type="wicri:Area/Ncbi/Checkpoint">005076</idno><idno type="wicri:doubleKey">0885-3185:1998:Gudex C:effect:of:dystonia</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of dystonia and botulinum toxin treatment on health-related quality of life.</title><author><name sortKey="Gudex, C M" sort="Gudex, C M" uniqKey="Gudex C" first="C M" last="Gudex">C M Gudex</name><affiliation wicri:level="1"><nlm:affiliation>Psychiatric Research Unit, Frederiksborg General Hospital, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Psychiatric Research Unit, Frederiksborg General Hospital</wicri:regionArea><wicri:noRegion>Frederiksborg General Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hawthorne, M R" sort="Hawthorne, M R" uniqKey="Hawthorne M" first="M R" last="Hawthorne">M R Hawthorne</name></author><author><name sortKey="Butler, A G" sort="Butler, A G" uniqKey="Butler A" first="A G" last="Butler">A G Butler</name></author><author><name sortKey="Duffey, P" sort="Duffey, P" uniqKey="Duffey P" first="P" last="Duffey">P. Duffey</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Botulinum Toxins (therapeutic use)</term><term>Chi-Square Distribution</term><term>Cohort Studies</term><term>Dystonia (drug therapy)</term><term>Dystonia (psychology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Quality of Life</term><term>Questionnaires</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Dystonia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Chi-Square Distribution</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Quality of Life</term><term>Questionnaires</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In view of the steadily rising demand for treatment of dystonia with botulinum toxin (BT), a relatively expensive neurologic paralytic agent, an exploratory study was undertaken to assess the extent to which dystonia and BT treatment affect the quality of people's lives. One hundred thirty adults with a current diagnosis of dystonia completed two generic measures of health-related quality of life (HRQoL) at regular intervals over a minimum of 6 months. One hundred two participants were receiving regular injections of BT; 28 were not taking BT. The HRQoL instruments used were the EuroQol and the Short Form 36 health survey questionnaire (SF-36). Compared with general population samples, study participants reported greater impairment on all EuroQol and SF-36 dimensions and gave a lower rating to their own health status. Participants with nonfocal dystonia had significantly more problems with usual activities than participants with focal dystonia, and a higher number had problems with mobility and self-care. The groups reported similar levels of pain and emotional well-being. Small improvements in HRQoL were seen after the administration of BT, although few of these were statistically significant. The study results offer further psychometric evidence for the discriminant and construct validity of both the EuroQol and the SF-36.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007F31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007F31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:A427930BFE364F3FACBEA4C18503E88BE303E701
|texte= Effect of dystonia and botulinum toxin treatment on health‐related quality of life
}}
| This area was generated with Dilib version V0.6.23. |  |